Navigation Links
IRICoR and Université de Montréal license a novel program for early-onset morbid obesity to Pfizer
Date:10/2/2013

This news release is available in French.

The Institute for Research in Immunology and Cancer Commercialization of Research (IRICoR) and its host institution, the Universit de Montral (UdM) today announced the licensing to Pfizer Inc. of a novel early-onset morbid obesity pre-clinical program developed at the Institute for Research in Immunology and Cancer (IRIC).

Under the terms of the global license, Pfizer will fund pre-clinical research activities at IRIC and will be fully responsible for the clinical development and marketing of any resulting products. Pfizer will make an upfront payment to IRICoR, and IRICoR will be eligible to receive development and commercial milestone payments, as well as a tiered royalty on any product sales.

In certain people, genetic defects in the cellular trafficking of the melanocortin receptor type 4 (MC4R) lead to an early-onset morbid obesity, resulting in multiple life-threatening problems, for example, an increased risk of cancer.

Dr. Michel Bouvier, world-renowned expert in the field of G-protein coupled receptor signaling, has developed a new therapeutic approach to this disease based on small molecule called "pharmacological chaperones" that selectively bind to MC4R and correct its folding, trafficking and function. Cell-based assays and pre-clinical studies using a new proprietary animal model for MC4R-promoted obesity indicate that this is a potentially promising approach for treating familial early-onset morbid obesity resulting from MC4R mutations.

"We are very pleased to partner with Pfizer for the development of this promising scientific breakthrough," commented Johane Boucher-Champagne, Chairperson of IRICoR's Board of Directors. "The ability of IRICoR to identify and incubate innovative projects which appeal to industry leaders such as Pfizer further validates our business model of forging collaborations between academia and industry for drug discovery and development. We look forward to working closely with Pfizer to potentially develop new treatment options for this indication."

"Dr. Bouvier's team brings leading expertise in GPCR pharmacological chaperones that will enrich Pfizer's already strong chaperone program targeting genetic diseases characterized by protein misfolding. The collaboration is designed to combine our capabilities and resources with the goal of expediting potential new therapies for early-onset morbid obesity patients with MCR4 mutations" said Kevin Lee, Chief Scientific Officer, Pfizer's Rare Disease Research Unit.


'/>"/>

Contact: William Raillant-Clark
w.raillant-clark@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Related biology news :

1. UdeMs IRIC and IRICoR achieve important milestone in their collaboration with Bristol-Myers Squibb
2. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
3. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
4. ORNLs newly licensed neutron detector will advance human disease research
5. Research spinoff ReXceptor gets license for Alzheimers treatment
6. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
7. Inflection Biosciences licenses preclinical oncology programs from the CNIO
8. Local Pearle Vision Licensee Adds Second Center In Canton, Ohio
9. Researchers discover novel therapy for Crohns disease
10. New clinical trial explores novel noninvasive colon cancer screening test
11. Notre Dame researchers using novel method to combat malaria drug resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at this ... leader in connected health and biometric measurement devices and services, will be ... On display in A&D Medical,s special CES Exhibit Suite , ... ongoing expansion of the company,s WellnessConnected product platform.  ... ...
(Date:1/3/2017)... 2017 Onitor, provider of digital health technology ... an innovative biometric data-driven program designed to aid weight ... the 2017 Consumer Electronics Show (CES) in ... U.S., the World Health Organization (WHO), have identified lifestyle ... who are overweight or obese. WHO also states that ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ), ... HealthCare, and Finance sectors announced today that Leaders in Community Alternatives ... deploy a community-based supportive services program to reduce recidivism in a ... its presence in the state. ... This new program, which is expected to commence in ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers and ... is a fully 21 CFR Part 11-compliant email client designed to provide product ...
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... , ... January 18, 2017 , ... ... Institutes of Health (NIH) to update its Data Sharing Policy. Specifically, the nation’s ... of grant applications subject to the existing policy. AMIA recommended that NIH earmark ...
Breaking Biology Technology: